$STRO Cashflow Statement | Understand Stock

$STRO

$8.87 -$0.02 (0.17%) Close

$STRO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization
Accretion of discount on marketable securities
Stock-based compensation
Non-cash lease expenses
Impairment charges
Realized gain on sale of equity securities
Unrealized gain on equity securities
Non-cash interest expense on deferred royalty obligation
Remeasurement of liability awards
Other
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other assets
Accounts payable
Accrued compensation
Other liabilities
Accrued expenses and other liabilities
Deferred revenue
Change in operating lease liability

Net cash used in operating activities
Investing activities
Purchases of marketable securities
Maturities of marketable securities
Sales of marketable securities
Proceeds from sale of equity securities, net
Purchases of equipment and leasehold improvements
Proceeds from exercise of options for Vaxcyte shares
Net cash provided by (used in) investing activities
Financing activities
Proceeds from sales of common stock, net of issuance costs
Proceeds from sales of common stock to Ipsen Biopharmaceuticals, Inc. (USA)
Payments of debt
Proceeds from the sale of future royalties, net of issuance costs
Proceeds from exercise of common stock options
Taxes paid related to net share settlement of restricted stock units
Return and retirement of common stock
Proceeds from employee stock purchase plan
Net cash provided by financing activities

Net increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
Supplemental disclosure of cash flow information
Cash paid for interest
Income tax paid
Supplemental Disclosures of Non-cash Investing and Financing Information
Purchase of property and equipment included in accounts payable
Value of 167,780 shares of Vaxcyte common stock received under the Vaxcyte Agreement
Financing Component Associated with Program Fees
Premium on common stock issued to Ipsen Biopharma, Inc. (USA)
Remeasurement of operating lease right-of-use assets for lease modification
Embedded interest associated with program fees

Comments